GEOVAX - Key Persons

Job Titles:

• Director, Vector Development

Dr. Domi has 20+ years of experience in poxviruses and vaccine development and was the inventor of the first infectious clone of a poxvirus genome cloned in bacteria. He received his PhD from the University of Paris, followed by post-doctoral training at the Jacques Monod Institute of Molecular Biology in Paris. Both his thesis and post-doctoral studies addressed the replication of vaccinia virus and the construction of cell lines for use in vaccine production. In addition, he worked 8 years in the laboratory of Dr. Bernie Moss as a Research Fellow NIAID, NIH. In 2008 he joined the International AIDS Vaccine Initiative (IAVI) laboratory in Brooklyn, New York, as a Principal Scientist and then as the head of Process Development and Virus Production at IAVI. In 2013 Dr. Domi joined GeoVax as Director of Vaccine Development.

Job Titles:

• Director, Project Management

Ashley joined the GeoVax team in 2022, bringing 12+ years of experience leading and developing projects in industry, academia, and non-profit settings. Upon completion of her graduate studies, she went directly into technical project management at Q 2 Solutions, an IQVIA company, directly prior to joining GeoVax. She brings a combination of specialized immunology expertise in inflammatory diseases across multiple therapeutic areas including oncology, autoimmune, and infectious diseases and broad knowledge of clinical and pre-clinical program development and management. Ashley received her PhD in Immunology and Microbiology from the University of Florida and her BS in Biochemistry from the Georgia Institute of Technology. More recently, she has obtained the globally recognized PMP certification from the Project Management Institute, which demonstrates industry-standard expertise in project management.

Job Titles:

• Professor of Medicine
• Scientific Advisory Board

Dr. Graham is Professor of Medicine and Microbiology, Biochemistry, & Immunology and Senior Advisor for Global Health Equity at Morehouse School of Medicine in Atlanta. He is the former deputy director of the Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). During his tenure at the VRC, Graham also served as chief of the Viral Pathogenesis Laboratory. Dr. Graham is an immunologist, virologist, and clinical trials physician whose primary interests are viral pathogenesis, immunity, and vaccine development. His work is focused on respiratory syncytial virus (RSV), influenza, coronaviruses, HIV, and other emerging viral diseases. After graduating from Rice University, Houston, TX, he obtained his MD from the University of Kansas School of Medicine in 1979. He then completed residency and two chief residencies in Internal Medicine, a fellowship in Infectious Diseases, and a PhD in Microbiology & Immunology at Vanderbilt University School of Medicine, Nashville, TN, where he rose to the rank of Professor of Medicine with a joint appointment in the Department of Microbiology & Immunology. In 2000, he became one of the founding investigators for the NIAID VRC at NIH, where he is now the Deputy Director and Chief of the Viral Pathogenesis Laboratory, and oversees the advanced development of VRC candidate vaccine products. He serves as a consultant for organizations involved in vaccine development for HIV, Tb, malaria, RSV, and emerging viral pathogens. His laboratory investigates basic mechanisms by which T cells affect viral clearance and immunopathology, explores mechanisms of antibody-mediated viral neutralization, and develops vaccine approaches against respiratory virus infections and emerging viral diseases.

Job Titles:

• CEO
• Chairman
• Leader
• President
• President, CEO & Director of Solvay Pharmaceuticals

David Dodd is a recognized leader with highly successful experience and expertise in transforming and restructuring public and private companies, establishing strong governance processes and operational discipline, resulting in operational improvements, significant revenue and enterprise value growth. During his career, he has overseen the approval of over 10 NDAs, over 15 acquisitions/divestitures, in excess of $2.5 billion in financial transactions and, led over $5 billion in incremental enterprise growth. Mr. Dodd joined the GeoVax Board of Directors in March 2010 and was elected Chairman in January 2011. Effective September 2018, he began serving also as the President, CEO. Mr. Dodd has led GeoVax through a significant transformation including a corporate recapitalization and up-listing to Nasdaq (September 2020), followed by the Company acquiring the exclusive worldwide rights to two Phase 2-status products. This included GEO-CM04S1, the most advanced next-generation vaccine for Covid-19 (currently in two Phase 2 trials) and Gedeptin®, a cancer immunotherapy in a multi-site Phase 2 trial, having received Orphan Drug designation from the FDA and, currently funded by the FDA Orphan Drugs Clinical Trials Program. In addition, significant strengthening of corporate governance, Board development and organizational capabilities have been implemented. Key highlights of his career prior to the GeoVax CEO position include: During Mr. Dodd's six-year tenure as President, CEO and Director of Serologicals Corporation (Nasdaq "SERO"), the market value of that company increased over $1 billion…from $85 million when he joined SERO to an all-cash sale to Millipore Corporation for $1.5 billion; Dodd served as President, CEO & Director of Solvay Pharmaceuticals, Inc., during which the enterprise value increased over $2 billion - from $100 million to $2.5 billion over a five-year period; He is a frequent invited speaker and panelist at business and economic development conferences, as well as various conferences focused on the life sciences and pharmaceutical industry. Mr. Dodd is a multi-year recipient of the FastTech 50 Growth Company Award while leading the transformation of Serologicals Corporation and, in 2022, he was selected as a recipient of the Georgia Titan 100 award. In addition, he has served on a development committee of the MacArthur Foundation, as an advisor to the First Minister of Scotland, as the Chair of the American Foundation for Suicide Prevention, as a member of the External Advisory Board of the Petit Institute for Bioengineering & Biosciences (GaTech), as the Chair of GaBio, as a board member on the Harvard Business School Healthcare Alumni Association and, in leadership roles with numerous additional organizations. Earlier in his career (1988), Mr. Dodd was recognized by the Los Angeles City Council for his leadership in establishing a developmental childcare facility in conjunction with Womens' Hospital in the East L.A. area. Mr. Dodd holds Bachelor of Science and Master of Science degrees from Georgia State University and completed the Harvard Business School of Advanced Management Program.

Job Titles:

• Board of Directors

Mr. Kollintzas joined the Board of Directors upon consummation of the merger with GeoVax, Inc. in September 2006. Since 2001 Mr. Kollintzas has been an intellectual property attorney specializing in biotechnology and pharmaceutical licensing, FDA regulation, and corporate/international transactions. Mr. Kollintzas received a microbiology degree from the University of Illinois and a J.D. from Franklin Pierce Law Center. He is a member of the Wisconsin and American Bar Associations. In 2014, he founded Procare Clinical, LLC, a clinical trial management company headquartered in Naperville, IL.

Job Titles:

• CEO
• Chairman
• Leader
• President
• Special Advisor
• Special Advisor to the Chairman, CEO and Board of Directors / President and CEO, Morehouse School of Medicine

As a physician, prominent infertility specialist, and researcher who has experience at the top levels of patient care as well as organizational management and public health policy, Valerie Montgomery Rice, MD, FACOG, brings an invaluable combination of skills and experience. As a transformational leader, she combines strategic thinking with transformational leadership to address challenging management issues. She has reinvented complex organizations' infrastructure to meet evolving strategic environments, positioning them for success through sustainability tactics. As the sixth president and chief executive officer of Morehouse School of Medicine (MSM), Montgomery Rice is the first woman in history to lead the freestanding medical institution. Between 2014 and 2021, she served as the institution's dean and president. Her tenure began at Morehouse School of Medicine in 2011, when she was appointed Dean and Executive Vice President. Aside from her work at MSM, Montgomery Rice has served as a faculty member and leader at various health centers, including academic health centers. As one of the nation's first centers dedicated to studying diseases that disproportionately affect women of color, she was founder of the Center for Women's Health Research at Meharry Medical College. A passionate advocate for health equity, Montgomery Rice is committed to enhancing pipeline opportunities for academically diverse learners, diversifying the physician and scientific workforce, as well as fostering equity in health outcomes and access to health care. Dr. Montgomery Rice was appointed special Advisor to the Chairman, CEO and Board of Directors of GeoVax Labs, Inc. in December 2022. Her affiliations include participation on a number of nonprofit and corporate boards such as: Advisory board member of the Historically Black Colleges and Universities Capital Financing Advisory Board, board of directors for UnitedHealth Group, Wellpath, 23&Me, Nemours, Chartis Health Equity Advisory Board, Georgia Research Alliance, CARE USA, Josiah Macy Jr Foundation, and Moffit Cancer Center (Institute). Among her efforts are the Danforth Dialogues podcast series: Leadership Lessons from the Frontlines of The Pandemic, which serves as a resource for faculty, staff, students, and the wider academic and professional community. Dr. Montgomery Rice was appointed to The President's Committee on the National Medal of Science by President Joe Biden in March 2022. Her memberships in the Horatio Alger Association and the National Academy of Medicine complement her distinguished career. Montgomery Rice was appointed in 2021 by Georgia Governor Brian Kemp to serve on the Georgia Commission on Women, where she utilizes her expertise and knowledge to improve the lives of women and their families. A number of accolades and honors have been bestowed upon Montgomery Rice over the years: The National Medical Association (NMA) bestowed its highest honor upon her, the Scroll of Merit Award (2023). Among STAT's 46 influential and important people in health, medicine, and science, Dr. Valerie Montgomery Rice landed on the 2023 STATUS List in academia. Georgia Trend Magazine selected Montgomery Rice as one of the 100 Most Influential Georgians from 2016-2018, again in 2021 & 2022. National Alumni Lifetime Achievement Award from National Medical Fellowships, Inc. (NMF, 2022). She was a 2022 recipient of the W. Montague Cobb Lifetime Achievement Award by the Cobb/NMA Health Institute. The American Jewish Committee Atlanta presented Montgomery Rice the National Human Relations Award in 2021. The Dean Griffin Community Service Award from the Georgia Institute of Technology, Girls Inc. 2019 Smart Award, The National Medical Association OB/GYN 2019 Legend of the Section Award, The Turknett Leadership Character Award (2018), Visions of Excellence Award, Atlanta Business League (2018), Links Incorporated Co-Founders Award (2018), She was named to the Horatio Alger Association of Distinguished Americans and received the 2017 Horatio Alger Award. Other honors include the following: Trumpet Vanguard Award (2015), The Dorothy I. Height Crystal Stair Award (2014), National Coalition of 100 Black Women - Women of Impact (2014), YWCA - Women of Achievement of Atlanta-(2014) and Nashville(2007), American Medical Women's Association Elizabeth Blackwell Medal (2011) and Working Mother Media Multicultural Women's Legacy Award (2011). A Georgia native, Montgomery Rice holds a bachelor's degree in chemistry from the Georgia Institute of Technology, a medical degree from Harvard Medical School, an honorary degree from the University of Massachusetts Medical School and a Doctor of Humane Letters honorary degree from Rush University. These achievements demonstrate her lifetime commitment to education, service, and advancing health equity. Her residency training in obstetrics and gynecology was at Emory University School of Medicine, while her fellowship training was at Hutzel Hospital for Reproductive Endocrinology and Infertility. With her husband, Melvin Rice Jr., a fellow graduate of the Georgia Institute of Technology, Montgomery Rice has two children: Jayne, an intern vascular surgeon at Harvard Medical School, and Melvin III, an Environment Artist for Virtual Production at Ringling College of Art and Design.

Job Titles:

• Director, Clinical Operations

Erica Raiden brings over thirty years of experience in project management, clinical research, and drug development. She has held positions of increasing responsibility supporting both the government and industry sectors, which is complimented by a unique blend of Sponsor and CRO experience. Upon joining GeoVax in 2022, Erica oversees the operational aspects of the company's clinical development programs. She received her Bachelor of Science in Biology with a Minor in Chemistry from Old Dominion University.

Job Titles:

• Company As Senior Vice President, Research and Development
• Scientific Co - Founder

Dr. Robinson joined the Company as Senior Vice President, Research and Development on a part-time basis in November 2007 and on a full-time basis in February 2008, and was promoted to Chief Scientific Officer in 2010. She was elected to the Board of Directors in June 2008. Dr. Robinson is the developer of GeoVax's HIV/AIDS vaccine technology and is one of the world's leaders in HIV/AIDS vaccine research. She co-founded GeoVax in 2001 to facilitate taking the AIDS vaccine developed in her laboratory at the Emory Vaccine Center in collaboration with scientists at the National Institutes of Health into the clinic. From 1999 to February 2008, Dr. Robinson served as the Asa Griggs Candler Professor of Microbiology and Immunology at Emory University in Atlanta, Georgia, and from 1998 to February 2008 as Chief, Division of Microbiology and Immunology, Yerkes National Primate Research Center. She was a Professor in the Department of Pathology at the University of Massachusetts Medical Center from 1988 to 1997 and Staff, then Senior, then Principal Scientist at the Worcester Foundation for Experimental Biology from 1977 to 1987. Dr. Robinson received a bachelor of arts degree from Swarthmore College and M.S. and Ph.D. degrees from the Massachusetts Institute of Technology.

Job Titles:

• Executive Medical Director, Oncology

Dr. Pipas is a medical oncologist who received his MD at SUNY-Health Science Center, Syracuse. He completed a residency in Internal Medicine at the Medical University of South Carolina in Charleston and a fellowship in Hematology/Oncology at Dartmouth. Following his training, he joined the faculty at Dartmouth Medical School and Dartmouth-Hitchcock Medical Center/Cancer Center. During an academic career that spanned more than 20 years, Dr. Pipas led the GI Oncology Program in the Cancer Center and served as both Director of the Office of Clinical Research and the Hematology/Oncology fellowship program. In addition, he spent many years as a member of both the Dartmouth College IRB and the Cancer Center Data and Safety Monitoring Board. He has published 40 scientific papers and more than 60 abstracts. Dr. Pipas' academic career was followed by more than six years of clinical development experience in oncology biotech companies. He joined GeoVax in January 2024 to assist with oncology asset development.

Job Titles:

• Board of Directors
• Cardiologist

Jayne Morgan, M.D. is a Cardiologist and the Executive Director of Health and Community Education at the Piedmont Healthcare Corporation in Atlanta, GA, the largest healthcare system in Georgia. Within this role she serves to address health literacy and information both internally to the 35,000 employee system, as well as to external stakeholders. Previously she served as the system Covid vaccine expert as the Executive Director of the Covid Task Force, analyzing the science and data from Piedmont and nationally, publishing 5 scientific articles, and driving efforts at addressing vaccine hesitancy and increasing vaccine uptake. In doing so, she created a social media series called The Stairwell Chronicles, providing up to date medical and scientific information in an easy to understand format. Dr. Morgan is the recipient of several awards acknowledging her work in providing accurate science and medicine to all communities including the NAACP Award, the National Women's Empowerment Award, the Atlanta Business Chronicle Award, and the Medical Association of GA Humanitarian Award. Further she serves as a CNN medical expert, holds an appointment as an Adjunct Assistant Professor of Medicine at The Morehouse School of Medicine, was selected to support the Department of Health in its series of "Ask The Experts", and has been a diligent and long time advocate for health equity for all communities via access to clinical trials. Dr. Morgan further serves on the Board of Georgia Bio, the Medical Association of Atlanta, and the National Board of the American Heart Association Diversity and Inclusion. Dr. Morgan is published in the areas of Congenital Heart Disease, Interventional Cardiology, and Covid19; serves as the Health Equity Advisor for Moderna, and is on Steering Committees of both Pfizer, and Novartis, where she also serves as the National Lead of the Horizon trial (Novartis). Previously she served as the Chief Medical Officer of the American Chemistry Council, Cardiology advisor to the MitraClip Team at Abbott Labs, the Global Director of the Cardiorenal Division of Solvay Pharmaceuticals, the Assistant Professor of Medicine at the Cleveland Clinic, and the first African American President of the Southeast Life Sciences Association (single largest biotech association in the Southeast). In her spare time she is a pilates enthusiast and holds multiple pilates certifications.

Job Titles:

• Head, Process Development and MFG

Jeff is a seasoned pharmaceutical bioprocessing & manufacturing executive with over 25+ years of experience in all aspects of biopharmaceutical development and manufacturing process development in cGMP and non-cGPM settings. Prior to his engagement with GeoVax starting in 2022, he held leadership positions with Emergent Biosolutions and Human Genome Sciences where he led the development and execution of strategies for process development, process characterization and various other manufacturing projects and investigations. Jeff will lead GeoVax's transition of manufacturing operations to its Contract Development and Manufacturing Organization (CDMO) provider. He received his Bachelor Degree in Chemical Engineering from the Massachusetts Institute of Technology.

Job Titles:

• Chairman of the Audit Committee
• Board of Directors
• Registered Certified Public Accountant

Mr. Spencer joined the Board of Directors in September 2006. Mr. Spencer is a registered Certified Public Accountant in four states, and he was a Partner at Ernst & Young LLP ("EY") where he spent more than 38 years until he retired in 2000. While at EY, Mr. Spencer was the partner in charge of the Firm's life sciences practice for the Southeastern United States, and his clients included numerous publicly owned and privately held medical technology companies. Since his retirement from EY, Mr. Spencer has served as the Audit Committee Chair on the Boards of ten other life sciences companies. He also served as the temporary Chief Financial Officer of a life sciences company while that company prepared for its initial public offering. In addition, he has served as a consultant to various companies with respect to financial accounting matters. Mr. Spencer earned a Bachelor of Science degree at Syracuse University and an MBA degree at Babson College. He also attended the Harvard Business School Advanced Management Program.

Job Titles:

• Head, Commercial Operations

John brings 4 decades of healthcare experience working in the pharmaceutical and medical device industries, as well as the clinical research and development sector. He has held senior positions in marketing, strategic planning, business development and general management. Prior to joining GeoVax in 2021 as the Head of Commercial Development & Operations, his most recent prior positions included the Executive Director of the Surgical Critical Care Initiative (SC2i), a precision medicine initiative at the Walter Reed National Military Medical Center and the Henry Jackson Foundation; System Director of the OhioHealth Research & Innovation Institute and CEO of PCTI Clinical Trials, Inc.. He also held positions at PAREXEL, CR Bard, Kendall Healthcare and Abbott. John holds a M.S. in Medical Physiology and a M.B.A. both from The Ohio State University.

Job Titles:

• Key Contributor
• VP, Business Development

Dr. Sharkey has been a key contributor to the development, acquisition, or divestment of multiple products with annual revenues ranging from $5 million to more than $2 billion dollars. Respected as a skillful negotiator capable of focusing the parties on relevant issues and mutual benefits, along with his extensive experience across multiple therapeutic, allows him to identify transactional structures which work for all parties involved. Prior to his current appointment as Vice-President of Business Development for GeoVax, he served as our part-time Head of Business Development, and was primary lead for the successful completion of two transformational transactions which propelled the company into Phase 2 programs in the areas of Covid-19 and Oncology. Previously, as CEO of Largent Health, LLC, he oversaw the development strategy for three 510(k) medical devices incorporating a proprietary antimicrobial technology, eventually leading to the registration and commercial launch of the 1st FDA cleared dental cavity cleanser with antimicrobial claims. In 2010, Dr. Sharkey founded Cogas Consulting, LLC, a consultancy providing executive management, technical development, regulatory and business development services to small and mid-size pharma and medical device companies. He has also assisted several companies in their financing activities. Prior to the above, he held senior executive positions within both Novartis and Shionogi and was involved in several notable partnering transactions including Novartis obtaining European rights to Lucentis® as well as global rights to Focalin® and Focalin® XR and Shionogi's global license for Osphena®. Dr. Sharkey holds a Ph.D. in Chemistry from the University of Buffalo and a B.S. in Chemistry from the State University of New York at Oneonta.

Job Titles:

• Chief Medical Officer

Dr. McKee has more than 35 years of experience in research and development from the bench to the bedside, with specific expertise in vaccines, emerging diseases, biodefense, and respiratory viral infections. After a 20 year career in the US Army, during which he held a variety of leadership roles in virology, immunology, preventive medicine, and clinical research and development at the Medical Research Institute of Infectious Diseases (USAMRIID) (Fort Detrick, MD,) and at Fort Bragg, NC, he retired as a Colonel in 2001. Dr. McKee then served briefly as State Epidemiologist in North Carolina, followed by roles as a contract physician investigator at USAMRIID, and as Senior Director of Clinical Research at DynPort Vaccine Company (Frederick, MD). He subsequently held multiple leadership positions, including Vice President and Managing Director of Public Health and Government Services, and Vice President for Vaccines and Public Health in the Infectious Diseases and Vaccines Center of Excellence, at Quintiles/QuintilesIMS (now IQVIA), and has served as Chief Medical Officer and Senior Medical and Scientific Advisor at Pharm-Olam International, as well as Chief Medical Officer at BravoVax, Ltd (Wuhan, China). He now provides contract clinical development services to the biopharmaceutical industry in infectious diseases and related areas. Over the course of a successful military and private-sector career, he has served as Principal Investigator on multiple Dept of Defense- and Dept of Health and Human Service-funded clinical studies, and has earned multiple board and advisory appointments, certifications, and medical/scientific society inductions. He has authored or co-authored more than 100 peer-reviewed publications and book chapters. Dr. McKee is a graduate of Davidson College (Davidson, NC), and received his medical degree from the University of Virginia School of Medicine (Charlottesville, VA), and his M.P.H. degree from the Johns Hopkins University School of Hygiene and Public Health (Baltimore, MD). He completed training in Pediatrics and Pediatric Infectious Diseases at Vanderbilt University Medical Center (Nashville, TN), and in Public Health and Preventive Medicine at the Walter Reed Army Institute of Research (Washington, DC). He is a Fellow of the American Academy of Pediatrics, American College of Preventive Medicine, and the Infectious Disease Society of America.

Job Titles:

• Chief Scientific Officer

Dr. Newman has more than 30+ years of experience in the biotechnology sector serving in senior management roles at GeoVax (Atlanta, GA), PaxVax (San Diego, CA), Pharmexa (Horsholm, Denmark), Epimmune (San Diego, CA), Vaxcel (Atlanta, GA), Apollon (Philadelphia, PA) and Cambridge Biotech (Boston, MA) where he directed research, development and early-stage clinical testing of protein, peptide, plasmid DNA and viral vectored vaccines and multiple vaccine adjuvants. He participated with or directed teams responsible for the transition of 10 vaccine or vaccine-related products from the research stage to Phase 1 and 2 clinical testing. He also served as the primary scientific director for multiple corporate teams that completed Due Diligence reviews, technology assessments and intellectual property review and portfolio management to support strategic planning, technology in-licensing and out-licensing, corporate partnering and mergers and acquisitions. Dr. Newman has co-authored more that 100 scientific papers, reviews and book chapters during his professional career. He is a named co-inventor on multiple issued US and PCT patents, all related to vaccine technologies. He served as the Principal Investigator on multiple USA government and foundation grants and contracts and has served as a grant and contract review expert for 20 years for National Institutes of Health. Dr. Newman is a graduate of the Ohio State University (B.Sc. and M.Sc.) and received his Ph.D. in Immunology from the John Curtin School of Medical Research, the Australian National University (Canberra, Australia). He completed four years post-doctoral training at Cornell University and the Uniformed Services University of Health Sciences under contract with the National Cancer Institute, National Institutes of Health. He also served four years as a full-time member of the Louisiana State University faculty at the School of Veterinary Medicine prior to joining the biotechnology industry in 1989.

Job Titles:

• Chief Financial Officer

Mark joined GeoVax in 2006 and currently serves as the Company's Chief Financial Officer. Prior to joining GeoVax, he served as Chief Financial Officer for HealthWatchSystems, Inc. a privately held company in the consumer healthcare industry; Chief Financial Officer for Duska Therapeutics, Inc., a publicly held biotechnology company; Chief Financial Officer of CytRx Corporation, a publicly held biopharmaceutical company. Mr. Reynolds began his career as an auditor with Arthur Andersen & Co. He is a certified public accountant and earned a Masters of Accountancy and Bachelor Degree in Accounting, both from the University of Georgia.

Job Titles:

• Director, Preclinical Research
• in 2018 As a Scientist

Dr. Hauser joined GeoVax in 2018 as a scientist and has since accepted the role of directing research programs to preclinical endpoint. Mary brings expertise in pathogen host interactions with over 15 years training on the topic. Her prior research in Virology & Immunology at University of Georgia and Virginia Tech Carilion Research Institute involved studies with multiple virus families and addressed key mechanisms viral fitness. Mary's experience gives distinctive insight into optimal design of prophylactics for infectious diseases. After receiving a BS in Chemistry from University of South Carolina, she obtained a Ph.D. in Microbiology & Immunology from Wake Forest University.

Job Titles:

• Fellow

Job Titles:

• Financial Executive
• Board of Directors
• Public Company Board Director

Nicole Lemerond is a public company board director and healthcare financial executive with over 25 years of experience in investment management, private equity, investment banking, mergers/acquisitions, and leveraged finance. She has significant experience executing complex transactions, managing diligence processes, raising capital and structuring balance sheets. Her breadth of industry expertise includes providers, payors, medical device manufacturers, HCIT providers, pharmaceutical and life sciences companies. Ms. Lemerond joined the board of GeoVax in August 2022 and is a member of the Audit Committee. She also serves on the boards of MediciNova and InMed Pharmaceuticals, where she chairs the Compensation Committees and is also a member of the Audit Committees. She has significant corporate governance experience and during her tenure as a board member, she has advised companies and management teams on multiple equity financings and capital raises, various business development opportunities and the hiring / onboarding of new c-suite executives and auditors. Ms. Lemerond has had significant experience in many different facets of finance throughout her career, working with both public and private company management teams and boards to increase stakeholder value. She has led diligence on and executed M&A, Reg D and leveraged finance transactions, totaling over $3 billion while at Lehman Brothers and The Carlyle Group. In addition, she established and led healthcare groups at leading investment firms in the process, raising over $1 billion of capital from institutional investors for these investment funds. Ms. Lemerond holds a Bachelor of Science degree from Cornell University and is a CFA charter holder.

Job Titles:

• Scientific Advisory Board
• University of Pittsburgh Distinguished Professor of Immunology

Dr. Finn is University of Pittsburgh Distinguished Professor of Immunology and Surgery and Founding Chair of the Department of Immunology, a position she held from 2001 to 2013. She was Program Leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute from 1991 to 2014. After receiving her PhD in Immunology at Stanford University in 1980, and completing her postdoctoral training there, Dr. Finn moved to Duke University and in 1991 to the University of Pittsburgh. She gained prominence through her original focus on transplantation biology and later through her basic and applied research focused on tumor antigens and the development of cancer vaccines. She has an extensive track record of research accomplishments reported in over 170 peer-reviewed papers and book chapters. She is the discoverer of the MUC1 tumor antigen, and has published extensively and continuously for the last 25 years on her basic and preclinical work on the development and evaluation of MUC1 cancer vaccines. She has been a co-investigator on a dozen clinical trials of various MUC1 vaccines in pancreatic, colon, breast, prostate, and lung cancers. Dr. Finn and her team also identified cyclin B1 as a tumor antigen and published several papers on its excellent potential as a cancer vaccine. She is on the editorial board of various cancer journals and on the advisory board of numerous cancer centers and several companies. She is an active member of the American Association of Immunologists where she served seven years as Council member and one year as President; a member of the American Association for Cancer Research; and past Chair of the Steering Committee of the AACR Cancer Immunology (CIMM) Working Group.

Job Titles:

• Board of Directors

Dr. Chase is a highly experienced biotech executive who has held senior leadership positions for companies in Canada, the United States and the United Kingdom including publicly traded companies listed on the TSX, Amex , Nasdaq and FTSE. Dr. Chase joined the GeoVax Board in March 2015 where he serves on the Audit Committee, the Governance Committee and Chairs the Compensation Committee. Dr. Chase began his career at Bristol Meyers and then as a Senior Vice President at Glaxo Canada where he was responsible for manufacturing, R&D, clinical and regulatory functions, as well as overseeing the building of new Canadian headquarters and a state-of-the-art manufacturing facility. Subsequently he held positions as President of Quadra Logic Technology; President of Pasteur Merieux Connaught Canada (where he negotiated the largest ever Canadian Government investment in a biotech company for research on potential cancer vaccines); President of North American Vaccine in Columbia, Maryland (where he oversaw the sale to Baxter); Biochem Pharma/Shire Biologics; and President of Immunovaccine (where he took the company public). He has held Board of Director roles in various vaccine/oncology companies/organizations including Biojet, Biotech Canada, Tissue Regeneration Therapeutics, Acambis, and Conjuchem. He is the former Chairman of the Board for Medimabs, Glysantis and Medicago (sold to Mitsubishi Tanabe). Dr. Chase graduated from Bishop's University with an honors biochemistry degree; received his PhD from the University of British Columbia. He conducted postgraduate research at the McArdle Cancer Institute at the University of Wisconsin. He attended the Senior Executive Program at the London Business School in the United Kingdom and has advised young entrepreneurs in his role as Entrepreneur in Residence for the University Health Network at the University of Toronto.

Job Titles:

• Board of Directors
• Fellow of the American Institute for Medical

Dr McNally's 40-year career spanned the medical biotech industry overseeing clinical research, quality and regulatory systems, and corporate management. As part of the management team, he brought CryoLife, Inc. from being one of the founders in 1984 to a listing on the NYSE in 1993. His numerous patents cover the preservation of human tissues for transplant which form the basis for the CryoLife portfolio of technologies for human heart valve, vein, artery, ligament, tendons, and menisci of the knee. In December 2006 he joined the GeoVax Board of Directors and in 2008 assumed the role of President and CEO until he retired at the end of August 2018. During his tenure the company was transformed from being a HIV (human immunodeficiency virus) vaccine development company to a company specializing in the development of vaccines for unmet diseases such as Ebola, Marburg, Zika and Malaria. Today those development efforts are being used for a vaccine to protect against Covid-19. Since his retirement, Dr. McNally remains on the GeoVax Board of Directors and serves as Lead Director as well as Chairman of the Nominating and Governance Committee. After graduating from Villanova University with a Bachelor of Science degree in Electrical Engineering he served two years at the United States Army Medical Research Laboratory, Ft Knox, Kentucky. Working with non-human primates he and his colleagues contributed to the medical literature for improved triage techniques for battle wound casualty cases. Following his military service, he attended the University of Pennsylvania and graduated with a Master of Science in Engineering (Biomedical) and Ph.D. in Biomedical Engineering. In 1976 his career focused on cardiac pacing, moving from clinical research to Manager of European Operations in 1980. Living four years in the United Kingdom he oversaw technical and business relationships for European cardiology physicians and local distributors for Pacesetter, Inc. and Intermedics, Inc. During that time in 1984 he was asked to join as one of the founders of CryoLife, Inc. as Senior Vice President for Clinical Research. After retiring from CryoLife, his industry consulting in 2000, led to being a co-founder and CEO of Cell Dynamics, LLC, a human cell line company specializing in the cGMP processing of human neonatal kidneys to extract cells used by Abbott Laboratories to manufacture AbbokinaseÒ a lifesaving blood clot busting drug. Dr. McNally is a Fellow of the American Institute for Medical and Biological Engineers and for 20 years served on the advisory boards of the Petit Institute for Bioengineering and Biosciences and the Dupree College of Management at the Georgia Institute of Technology and was an occasional lecturer. He is a former Chairman and 20-year member of the board for Georgia BIO, the bio industry trade association for the State of Georgia. Currently he serves on the Villanova University Engineering School Entrepreneurship Advisory Board and mentors student project teams. In 2020 he received the highest Villanova Engineering alumni award for career achievement. In 2014 he gave the December Commencement address for the College of Mathematics and Science and Business School for Kennesaw State University. Over his career he has given countless corporate presentations and numerous print and TV interviews.

Job Titles:

• Is Director of the University
• Scientific Advisory Board

Dr. Weaver is Director of the University of Texas Medical Branch (UTMB) Institute for Human Infections and Immunity and the Scientific Director of the Galveston National Laboratory. Dr. Weaver, an internationally recognized virologist and vector biologist, studies arthropod-borne viruses (arboviruses), their transmission by mosquitoes, and develops vaccines to control the diseases that they cause. His research encompasses the ecology and epidemiology of enzootic arbovirus transmission cycles, virus-mosquito interactions, pathogenesis, and emergence mechanisms of epidemic strains. He has also developed promising new vaccines against several alphaviruses; the chikungunya vaccine developed in his laboratory, licensed to Takeda Pharmaceuticals and patented in 19 countries, is in late preclinical development. Dr. Weaver's research has led to over 270 peer-reviewed publications in scientific journals, and 75 reviews and book chapters. In 2014, Dr. Weaver received the Walter Reed Medal, awarded every three years by the American Society of Tropical Medicine and Hygiene for distinguished career accomplishments in tropical medicine research. His many national and international leadership roles include his current role as Chair of the Global Virus Network's Chikungunya and Zika Task Forces. He also serves as an editor for several major tropical medicine and microbiology journals.

Job Titles:

• Senior Scientist

Sreenivasa joined GeoVax in 2020 with twenty years of research experience in molecular cell biology and immunology. Under the mentorship of Dr. Thomas Grundstrom at Umea University (Sweden), he completed a Ph.D. in Molecular Biology on the regulation of NF-kB transcription factor by calcium signaling in T cells. In 2011, he pursued postdoctoral training in the laboratory of Dr. Judy Cannon at the University of New Mexico, where he acquired knowledge of T cell immunology through research about T cell migration, both in cancer and infection models. He is a key member of the research and development team at GeoVax and assists in developing and accessing vaccine efficacy and immunogenicity.

Job Titles:

• Professor Emeritus at the University of Pennsylvania
• Scientific Advisory Board

Dr. Plotkin is Professor Emeritus at the University of Pennsylvania in Philadelphia, PA and Adjunct Professor at the Johns Hopkins University, Baltimore, MD. Until 1991, he was Professor of Pediatrics and Microbiology at the University of Pennsylvania, Professor of Virology at the Wistar Institute, and at the same time, Director of Infectious Diseases and Senior Physician at the Children's Hospital of Philadelphia. In 1991, Dr. Plotkin left the University to join the vaccine manufacturer Pasteur-Mérieux-Connaught (now Sanofi Pasteur), based in Marnes-la-Coquette, outside Paris, where he held the title of Medical and Scientific Director for seven years. Dr. Plotkin developed the rubella vaccine now in standard use throughout the world, is co-developer of the pentavalent rotavirus vaccine, and has worked extensively on the development and application of other vaccines including anthrax, oral polio, rabies, varicella, and cytomegalovirus. Dr. Plotkin's bibliography includes nearly 800 articles, and he has edited several books including the standard textbook on vaccines - ‘Vaccines' - now in its 6th edition. He is a consultant to vaccine manufacturers, biotechnology companies, and non-profit research organizations as principal of Vaxconsult, LLC. Dr. Plotkin attended New York University, where he received a B.A. degree, and the State University of New York Medical School in Brooklyn, where he received an M.D. degree in 1956. He has been chairman of the Infectious Diseases Committee and the AIDS Task Force of the American Academy of Pediatrics, liaison member of the Advisory Committee on Immunization Practices, and Chairman of the Microbiology and Infectious Diseases Research Committee of the National Institutes of Health. Dr. Plotkin has been the recipient of numerous awards and honors during his distinguished career.

Job Titles:

• VP, Regulatory Affairs

With over thirty-years of experience in biopharmaceutical regulatory management and consulting, Terri joined GeoVax in 2023. Having held prior leadership roles with Genpact, Teva Pharmaceuticals, Pfizer, Centocor and MedImmune, Terri brings a broad view across the regulatory landscape having experience in regulatory strategy development, regulatory oversight of clinical trials, and the direct interaction with US and International Regulatory Authorities including submissions, inspections and reporting. She received her MS in Biotechnology from Johns Hopkins University and BS in Biology from William Paterson University.

Job Titles:

• VP, Quality Systems and Compliance

Bringing twenty-nine years of quality assurance experience in biologics, vaccines, personalized medicine, and cell therapy Quality Assurance and Quality Control, Tom joined GeoVax in 2023. He has held roles in Quality management, QC laboratory management and testing with several biopharmaceutical organizations including Vedanta Biosciences, Genocea Biosciences, Shire, Wyeth and Pfizer. Tom brings broad expertise in the Quality Assurance/Control space specifically within Quality operations, audits, product technical transfer, validation, facility start-up, clinical product development and regulatory filings. He received his BS in Biology from the University of Massachusetts Amherst.